MTAMRIO
DEAD

Serial Number

88408993

Owner

Mirati Therapeutics, Inc.

Attorney

Eric R. Moran

Filing Date

Apr 30, 2019

Add to watchlist:

No watchlists yet
View on USPTO

MTAMRIO Trademark

Serial Number: 88408993

MTAMRIO is a trademark filed by Mirati Therapeutics, Inc. on April 30, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Mirati Therapeutics, Inc. (34 trademarks)

San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

April 30, 2019

Registration Date

Not Registered

Published for Opposition

September 8, 2020

Goods & Services

pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceutical preparations for the treatment of squamous cell carcinoma; pharmaceutical preparations for the treatment of head and neck squamous cell carcinoma; pharmaceutical preparations for the treatment of oral cavity squamous cell carcinoma; pharmaceutical preparations for the treatment of colorectal cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules for the treatment of squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of head and neck squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of oral cavity squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for use in oncology; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of bladder cancer; pharmaceutical products for the treatment of lung cancer; pharmaceutical products for the treatment of renal cancer; pharmaceutical products for the treatment of renal cell carcinoma; pharmaceutical products for the treatment of squamous cell carcinoma; pharmaceutical products for the treatment of head and neck squamous cell carcinoma; pharmaceutical products for the treatment of oral cavity squamous cell carcinoma; pharmaceutical products for the treatment of colorectal cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors

research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 5, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 5, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 29, 2022 EXRA
SOU EXTENSION 3 GRANTED
Apr 27, 2022 EX3G
SOU EXTENSION 3 FILED
Apr 27, 2022 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 27, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 8, 2021 EXRA
SOU EXTENSION 2 GRANTED
Oct 6, 2021 EX2G
SOU EXTENSION 2 FILED
Oct 6, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 6, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 29, 2021 EXRA
SOU EXTENSION 1 GRANTED
Apr 27, 2021 EX1G
SOU EXTENSION 1 FILED
Apr 27, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 27, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 3, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 8, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 8, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 19, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 3, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 24, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 23, 2020 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 23, 2020 ERFR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 4, 2020 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 4, 2020 COAR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 25, 2020 GNFN
FINAL REFUSAL E-MAILED
Jan 25, 2020 GNFR
FINAL REFUSAL WRITTEN
Jan 25, 2020 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 14, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 14, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 14, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 15, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jul 15, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jul 15, 2019 CNRT
ASSIGNED TO EXAMINER
Jul 12, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 16, 2019 NWOS
NEW APPLICATION ENTERED
May 3, 2019 NWAP